ITUS Corporation Releases Results for Cchek™ Breast Cancer Study
SAN JOSE, Calif., July 30, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS) today announced that it has released interim data from a breast cancer study using its Cchek™ non-invasive (utilizing a blood sample), artificial intelligence (AI) guided, liquid biopsy cancer detection platform, that showed significantly better results in sensitivity, specificity, and overall accuracy than mammography.
The Cchek™ breast cancer study is focused on early stage cancer, because other methods are poor at accurately identifying stage 1 and 2 malignancies. The interim results showed sensitivity of 92% and specificity of 87% for stage 1 and 2 cancers. The interim data utilized blood samples from a total of 144 patients, that included 64 women who had biopsy verified breast cancer, and 80 women with no cancer. Our AI application was trained with 88 patients and tested with 56. As later stage patients are added to the study, performance is expected to improve.
Dr. Amit Kumar, CEO of ITUS stated, "As previously announced, our two primary areas of focus for Cchek™ are prostate cancer and breast cancer. While our sample size is still small compared to the amount of data available from mammography, we are encouraged by our results and believe that as we accumulate more patient data, our results will continue to surpass mammography. We are focused on developing this test for identifying early (Stage 1 and 2) breast cancers, and plan to initially commercialize it for confirmatory testing."
While the initial focus will be on confirmatory testing, ITUS believes Cchek™ can eventually be used for multiple markets including confirmatory testing, recurrence testing, therapy monitoring, as well as screening. Existing confirmatory diagnostics for many cancers rely on traditional biopsies, which can be painful, expensive, and result in dangerous side effects. ITUS hopes its unique liquid biopsy approach will significantly improve upon current standards of care. Further, ITUS is evaluating whether Cchek™ may be utilized to distinguish between responders and non-responders to immune-therapies.
ITUS, a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer. Its wholly owned subsidiary, Anixa Diagnostics Corporation, is developing the CchekTM platform, a series of non-invasive blood tests for the early detection of solid tumor based cancers, which is based on the body's immunological response to the presence of a malignancy. Its majority owned subsidiary, Certainty Therapeutics, Inc., is developing CAR-T based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. ITUS also continually examines emerging technologies in complementary or related fields for further development and commercialization. Additional information is available at www.ITUScorp.com.
Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect ITUS Corporation's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.